*Search results from clinicaltrials

Preview:

DESCRIPTION

Anti-PD-1/PD-L1 Pipeline Comparison. *Search results from clinicaltrials.gov - PowerPoint PPT Presentation

Citation preview

Compound Hits * Development Status/Approved indications

Indications in development Combination partners

MSD/Keytruda

(anti-PD-1)

23 Approved/mMelanoma (2nd line, USA)

RCC, NSCLC, H&N, BC, MM +Cytotoxics+ipilimumab

BMS/Ono/Opdivo

(anti-PD-1)

46 Approved/Unresectable melanoma (JP)

Squamous cell NSCLC(3rd line, EU registration)Non-sq NSCLC, mRCC, CML, mCRC, GBM, H&N, NHL, HL, MM, DLBCL

+Cytotoxics+ipilimumab (Anti-CTLA4)+bevacizumab+cetuximab+urelumab (Anti-CD137)+Anti-LAG-3 mAb (Anti-LAG-3)+Anti-KIR mAb (Anti-KIR)

Roche/RG7446

(MPDL3280)(anti-PD-L1)

13 P3 Melanoma, RCC, NSCLC, BC +ipilimumab (anti-CTLA4)+vemurafinib+Avastin+Tarceva+obinutuzumab+cobimetinib

AstraZeneca/MEDI4736

(anti-PD-L1)

17 P3 Melanoma, mNSCLC, H&N, CRC,

+anti-PD-1 mAb (MEDI0680)+tremelimumab(Anti-CTLA4)+EGFR Tkietc

*Search results from clinicaltrials.govRCC(renal cell carcinoma), NSCLC(non-small cell lung cancer, H&N(head &neck), BC(bladder cancer), MM (multiple myeloma), CML(chronic myeloid leukemia), GBM(Glioblastoma Multiforme), NHL (non-Hodgkin lymphoma), HL (Hodgkin lymphoma), DLBCL(diffuse large B cell lymphoma)

Anti-PD-1/PD-L1 Pipeline Comparison